Since several CRHR1 antagonists, such as non-peptide CRHR1 antagonists, have been proven to be effective for the alleviation of IBD via the blockade of colonic hypersensitivity induced by colonic inflammatory reaction, thus providing a novel therapeutic options in the treatment of stress-aggravated IBD33,34, whether these antagonisms affect autophagy and gut microbiota may be interesting questions. This evidence concerns the gene CRHR1 and inflammatory bowel disease.